- Personal FinanceCompare Online BrokersTop StocksAlternative Investing
- CryptoGet StartedNFTs
Reata Pharmaceuticals (NASDAQ:RETA), Quotes and News Summary
Reata Pharmaceuticals (NASDAQ: RETA)
Earnings
see more| Q2 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | (EXPECTED)2022-08-08 | ||||||
| REV | |||||||
| Q1 2022 | Est. | Actual | Surprise | ||||
|---|---|---|---|---|---|---|---|
| EPS | -2.150 | -1.330 | 0.8200 | ||||
| REV | 1.550M | 914.000K | -636.000K |
Analyst Ratings
see more| Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
|---|
Reata Pharmaceuticals Questions & Answers
You can purchase shares of Reata Pharmaceuticals (NASDAQ: RETA) through any online brokerage.
Other companies in Reata Pharmaceuticals’s space includes: Theravance Biopharma (NASDAQ:TBPH), CinCor Pharma (NASDAQ:CINC), Sundial Growers (NASDAQ:SNDL), Supernus Pharmaceuticals (NASDAQ:SUPN) and Phibro Animal Health (NASDAQ:PAHC).
The latest price target for Reata Pharmaceuticals (NASDAQ: RETA) was reported by Citigroup on Friday, May 27, 2022. The analyst firm set a price target for 46.00 expecting RETA to rise to within 12 months (a possible 39.39% upside). 9 analyst firms have reported ratings in the last year.
The stock price for Reata Pharmaceuticals (NASDAQ: RETA) is $33 last updated Today at June 27, 2022, 6:35 PM UTC.
There are no upcoming dividends for Reata Pharmaceuticals.
Reata Pharmaceuticals’s Q2 earnings are confirmed for Monday, August 8, 2022.
There is no upcoming split for Reata Pharmaceuticals.
Reata Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.